Vincent E. Weynants
Rixensart, WAL, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Corrigendum to How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects? Vaccine. 2024 Oct 24;42(24):126215. doi: 10.1016/j.vaccine.2024.126215. Epub 2024 Aug 29. PMID: 39213982.
Journal: Vaccine
Published: January 11, 2025
Correction to: Ex-vivo RNA expression analysis of vaccine candidate genes in COPD sputum samples.
Journal: Respiratory research
Published: May 29, 2024
Cytokine Biomarkers of Exacerbations in Sputum From Patients With Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study.
Journal: The Journal of infectious diseases
Published: October 20, 2023
How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects?
Journal: Vaccine
Published: October 07, 2023
Impact of bacterial strain acquisition in the lung of patients with COPD: the AERIS study.
Journal: Infectious diseases (London, England)
Published: July 07, 2022
Ex-vivo RNA expression analysis of vaccine candidate genes in COPD sputum samples.
Journal: Respiratory research
Published: January 19, 2022
UspA2 is a cross-protective Moraxella catarrhalis vaccine antigen.
Journal: Vaccine
Published: June 09, 2021
A Protein E-PilA Fusion Protein Shows Vaccine Potential against Nontypeable Haemophilus influenzae in Mice and Chinchillas.
Journal: Infection and immunity
Published: May 10, 2019
Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations.
Journal: Thorax
Published: April 16, 2017
Interleukin-22 protects against non-typeable Haemophilus influenzae infection: alteration during chronic obstructive pulmonary disease.
Journal: Mucosal immunology
Published: September 28, 2015
Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins.
Journal: Infection and immunity
Published: December 03, 2014
Last Updated: 09/26/2026